Here is an update on recent en banc activity at the Federal Circuit in patent cases. Highlights include a new petition in a pro se patent case and two new invitations for responses in patent cases raising questions related to obviousness and reduction to practice. The court also denied a petition in a patent case raising questions related to construction of alleged means-plus-function limitations. Here are the details.
New Petition
Since our last update, a new petition was filed in Askan v. FARO Technologies, Inc., a pro se patent case.
New Invitations for Responses
The Federal Circuit invited responses to the petitions in the following two cases:
- Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (obviousness)
- Medtronic, Inc. v. Teleflex Innovations S.A.R.L. (reduction to practice)
New Denial
Since our last update, the Federal Circuit denied the petition in XR Communications, LLC v. ARRIS Solutions, Inc., a patent case presenting questions related to construction of alleged means-plus-function limitations.